Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 94%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,686
Total Claims
$1.2M
Drug Cost
703
Beneficiaries
$1,677
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+47%
Opioid rate vs peers
3.3% vs 2.2% avg
+19%
Cost per patient vs peers
$1,677 vs $1,411 avg
+3%
Brand preference vs peers
11.0% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
3.3%
Opioid Rate
385
Opioid Claims
$8,307
Opioid Cost
13.2%
Long-Acting Rate
Brand vs Generic
Brand: 1,278 claims · $884K
Generic: 10,350 claims · $292K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Rivaroxaban | 189 | $181K |
| Apixaban | 111 | $90K |
| Insulin Glargine,hum.Rec.Anlog | 75 | $74K |
| Dulaglutide | 69 | $73K |
| Insulin Aspart | 41 | $56K |
| Glatiramer Acetate | 13 | $53K |
| Insulin Lispro | 29 | $31K |
| Empagliflozin | 24 | $30K |
| Cenobamate | 17 | $23K |
| Insulin Lispro | 15 | $22K |
| Insulin Glargine,hum.Rec.Anlog | 18 | $22K |
| Semaglutide | 13 | $21K |
| Mirabegron | 28 | $20K |
| Tirzepatide | 13 | $20K |
| Fluticasone/Umeclidin/Vilanter | 19 | $18K |
Prescribing Profile
Patient Profile
76
Avg Age
55%
Female
1.40
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About